• 1
    Vane J. Towards a better aspirin. Nature 1994; 367: 2156.
  • 2
    O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 15660.
  • 3
    O'Banion MK, Sadowsky HB, Winn Y, Young DA. A serum and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 232617.
  • 4
    Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100: 13259.
  • 5
    Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 44249.
  • 6
    Eling TE, Curtis JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 1992; 53: 26173.
  • 7
    Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 37859.
  • 8
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 11838.
  • 9
    Kim Y, Fischer SM. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. J Biol Chem 1998; 273: 2768894.
  • 10
    Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 435662.
  • 11
    Okamoto T, Hino O. Expression of cyclooxygenases-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of basal level of mRNA. Int J Mol Med 2000; 6: 4557.
  • 12
    Khan KN, Stanfield KM, Trajkovic D, Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001; 38: 1169.
  • 13
    Hino O, Fukuda T, Satake N, Kobayashi T, Honda S, Orimoto K, Yamashita Y, Kikuchi Y. TSC2 gene mutant (Eker) rat model of a Mendelian dominantly inherited cancer. Prog Exp Tumor Res Basal Karger 1999; 35: 95108.
  • 14
    Hino O, Majima S, Kobayashi T, Honda S, Momose S, Kikuchi Y, Mitani H. Multistep renal carcinogenesis as gene expression disease in tumor suppressor TSC2 gene mutant model–genotype, phenotype and environment. Mutat Res 2000; 477: 15564.
  • 15
    Hino O, Kobayashi T, Tsuchiya H, Kikuchi Y, Kobayashi E, Mitani H, Hirayama Y. The predisposing gene of the Eker rat inherited cancer syndrome is tightly linked to the tuberous sclerosis (Tsc2) gene. Biochem Biophys Res Commun 1994; 203: 13028.
  • 16
    Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995; 9: 704.
  • 17
    Orimoto K, Tsuchiya H, Kobayashi T, Matsuda T, Hino O. Suppression of the neoplastic phenotype by replacement of the Tsc2 gene in Eker rat renal carcinoma cells. Biochem Biophys Res Commun 1996; 219: 707.
  • 18
    Okamoto T, Furuya M, Yamakawa T, Yamamura K, Hino O. TNF-α gene expression in the liver of the IFN-γ transgenic mouse with chronic active hepatitis. Biochem Biophys Res Commun 1996; 226: 7628.
  • 19
    Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KP, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary non-polyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999; 117: 3508.
  • 20
    Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58 (2 Suppl 1): 12731.
  • 21
    Gaffney DK, Holden J, Zempolich K, Murphy KJ, Dicker AP, Dodson M. Elevated COX-2 expression in cervical carcinoma reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001; 24: 4436.
  • 22
    Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 18893.
  • 23
    Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwang E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in APC delta 176 knockout mice by inhibition of cyclooxygenase 2 (Cox-2). Cell 1996; 87: 8039.
  • 24
    Son HJ, Kim YH, Park DI, Kim JJ, Rhee PL, Paik SW, Choi KW, Song SY, Rhee JC. Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer. J Clin Gastroenterol 2001; 33: 3838.
  • 25
    Rajnakova A, Moochhala S, Goh PM, Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001; 30: 17785.
  • 26
    Klimp AH, Hollema H, Kempinga C, van der Ze EG, de Vries AG, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001; 61: 73059.
  • 27
    Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002; 23: 14636.